In line with these findings, Poole and colleagues demonstrated that in BL cells inhibition of HSP90 is able to reduce MYC levels by blocking its transcription and increasing its degradation, suggesting that HSP90 inhibitors may provide an alternative approach in BL treatment [97]. The gene discussed is MYC; the disease is Burkitt lymphoma.